Compumedics Limited (ASX:CMP) Chairman's Address to Shareholders
Compumedics Limited (ASX:CMP) is a leading global, innovative developer and manufacturer of medical devices.
Compumedics Limited (ASX:CMP) is a leading global, innovative developer and manufacturer of medical devices.
The four patients who took part in Living Cell Technologies Limited's (ASX:LCT) (OTCMKTS:LVCLY) Phase I/IIa clinical study of NTCELL(R) for Parkinson's disease have all reached the milestone of 42 weeks post-implant. All four patients remain well, and there are no safety concerns.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the first patient has been enrolled and safely treated in the first clinical trial of RGSH4K, the company's autologous tumour vaccine product for the treatment of solid tumours.
Compumedics Limited (ASX:CMP) is pleased to announce the release of an initiating research report by PAC partners.
Erin Resources Ltd (ASX:ERI) is pleased to provide investors an update on the development of MGC Pharmaceuticals' (MGC) new CBD based skin care formula for the effective relief for Psoriatic skin.
Regeneus Ltd (ASX:RGS) are pleased to provide the Company's Annual Report for 2015 to shareholders.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $3.4m from the Australian Government's Research and Development Tax Incentive Program for activities conducted during the 2015 financial year.